ECO Animal Health Group (LON:EAH) Stock Passes Above Fifty Day Moving Average – What’s Next?

ECO Animal Health Group plc (LON:EAH)’s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 92.14 and traded as high as GBX 107. ECO Animal Health Group shares last traded at GBX 97.50, with a volume of 62,743 shares traded.

Wall Street Analysts Forecast Growth

Separately, Shore Capital upped their target price on shares of ECO Animal Health Group from GBX 150 to GBX 160 and gave the company a “buy” rating in a report on Tuesday, December 2nd. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of GBX 160.

ECO Animal Health Group Stock Down 4.4%

The firm has a fifty day moving average price of GBX 92.14 and a 200-day moving average price of GBX 80.16. The company has a quick ratio of 2.14, a current ratio of 2.96 and a debt-to-equity ratio of 4.81. The firm has a market cap of £65.41 million, a price-to-earnings ratio of 22.21 and a beta of -0.05.

ECO Animal Health Group (LON:EAH) last announced its quarterly earnings data on Monday, December 1st. The company reported GBX (0.54) earnings per share (EPS) for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 1.27%.

Insider Activity at ECO Animal Health Group

In related news, insider David Hallas bought 18,348 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was bought at an average price of GBX 109 per share, with a total value of £19,999.32. 11.14% of the stock is currently owned by corporate insiders.

ECO Animal Health Group Company Profile

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.